c-Met-IN-12

Cat. No.:	HY-147695
CAS No.:	2426675-70-7
Molecular Formula:	$C_{34}H_{29}FN_4O_4$
Molecular Weight:	576.62
Target:	c-Met/HGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC_{50} of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy[1].
IC_{50} & Target	c-Met 10.6 nM (IC_{50})
In Vivo	c-Met-IN-12 (compound 4r) (Tumor-bearing nude mice, 45 mg/kg, Orally, Q.D. for 21 days) exhibits significant tumor growth inhibition (93%) in a U-87MG human gliobastoma xenograft model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Xu H, et al. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2. Bioorg Med Chem. 2020 Jun 15;28(12):115555.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA